Replies to post #55909 on Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

In a research report published today, H.C. Wainwright analyst Reni Benjamin reiterated a Buy rating on Ariad Pharma (NASDAQ:ARIA) but cut his price target to $8 (from $14), following the company’s release of its third-quarter results.

Lots of $8's now,..... and some $4's

[dubstock]

I don't know how well I trust the projections of an analyst ranked in the bottom one percent of his peers...